New combo therapy aims to treat prostate cancer with fewer side effects
NCT ID NCT05790213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining focal prostate ablation (a surgery that destroys only the cancerous part of the prostate) with a short course of hormone therapy can effectively treat intermediate-risk prostate cancer. The study will enroll 57 participants and measure how well the treatment controls cancer, as well as its impact on quality of life and side effects. The goal is to find a less invasive option that preserves healthy tissue and reduces long-term complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Androgen deprivation therapy (hormone therapy) and focal prostate ablation (surgery to destroy part of the prostate)
What this could lead to
If successful, this combination could offer a less invasive treatment option for intermediate-risk prostate cancer, potentially reducing side effects compared to whole-gland treatments.
What could go wrong
This is a small, early-phase trial with only 57 participants, so results may not apply to everyone. The treatment may not fully eliminate the cancer, and side effects from hormone therapy or the procedure are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UChicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••